Nuvaxovid 2026-27 Injection, Suspension
NDC Package 49281-026-50

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Nuvaxovid 2026-27 (nvx-cov2928) injection is nUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).NUVAXOVID is approved for use in individuals who are:65 years of age and older, or12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. This formulation utilizes a injection, suspension delivery system. Marketed by Sanofi Vaccines Us Inc., this product is identified by NDC 49281-026 and is authorized under FDA application BLA125817.

Identification & Billing

NDC Package Code
49281-026-50
Package Description
10 SYRINGE in 1 CARTON / .5 mL in 1 SYRINGE (49281-026-88)
Product Code
49281-026
11-Digit Billing Format
49281002650

Clinical Specifications

Proprietary Name
Nuvaxovid 2026-27
Non-Proprietary Name
Nvx-cov2928
Substance Name
Nvx-cov2928
Dosage Form
Injection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route
Intramuscular - Administration within a muscle.
Active Ingredient(s)
NVX-COV2928 5 ug/.5mL
Usage Information
NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).NUVAXOVID is approved for use in individuals who are:65 years of age and older, or12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

Regulatory & Marketing

Labeler Name
Sanofi Vaccines Us Inc.
Product Type
Vaccine
FDA Application #
BLA125817
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
08-27-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 49281-026-50 identifies a specific commercial package of 10 syringe in 1 carton / .5 ml in 1 syringe (49281-026-88) of Nuvaxovid 2026-27, a vaccine label labeled by Sanofi Vaccines Us Inc.. This injection, suspension is formulated for intramuscular use and contains nvx-cov2928 as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi Vaccines Us Inc. on August 27, 2026. The current certification is valid through December 31, 2027.

How is this Sanofi Vaccines Us Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 49281002650. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
49281-026-50
11-Digit CMS (5-4-2)
49281-0026-50

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.